17.87
전일 마감가:
$17.92
열려 있는:
$17.87
하루 거래량:
2.73M
Relative Volume:
1.99
시가총액:
$1.76B
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-38.02
EPS:
-0.47
순현금흐름:
$-44.23M
1주 성능:
-0.28%
1개월 성능:
+3.53%
6개월 성능:
+26.92%
1년 성능:
+59.70%
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SPRY
Ars Pharmaceuticals Inc
|
17.87 | 1.76B | 0 | -44.84M | -44.23M | -0.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-07 | 개시 | Scotiabank | Sector Outperform |
2025-02-10 | 개시 | Oppenheimer | Outperform |
2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2024-08-12 | 재확인 | Leerink Partners | Outperform |
2024-07-25 | 개시 | Raymond James | Outperform |
2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2023-01-31 | 개시 | Wedbush | Outperform |
2023-01-03 | 개시 | William Blair | Outperform |
2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
When is ARS Pharmaceuticals Inc. stock expected to show significant growthUnlock your portfolio’s hidden potential - jammulinksnews.com
Should I hold or sell ARS Pharmaceuticals Inc. stock in 2025Consistent double returns - jammulinksnews.com
ARS Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough financial growth - PrintWeekIndia
Is ARS Pharmaceuticals Inc. a good long term investmentTriple-digit return opportunities - PrintWeekIndia
What drives ARS Pharmaceuticals Inc. stock priceTremendous growth opportunities - Autocar Professional
What analysts say about ARS Pharmaceuticals Inc. stockBreakthrough stock performance - jammulinksnews.com
MHRA approves needle-free adrenaline nasal spray for anaphylaxis - Yahoo Finance
EURneffy® (adrenaline nasal spray) Approved in the U.K. as - GlobeNewswire
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? - Yahoo Finance
What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' - Yahoo Finance
ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine (SPRY) - Seeking Alpha
(SPRY) Technical Data - news.stocktradersdaily.com
ARS Pharmaceuticals: 'Betting On The Come' (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals: Insider Liquidity vs. Institutional Buying – A Contrarian Opportunity? - AInvest
ARS Pharmaceuticals: Navigating Insider Sales Amid Growth Catalysts - AInvest
Raymond James reiterates strong buy on ARS Pharmaceuticals stock - Investing.com
ARS Pharmaceuticals (SPRY) Soars 4.48% on Earnings, Partnership - AInvest
ARS Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
High Growth Tech Stocks in US for June 2025 - simplywall.st
Ars pharma CCO Karas sells $240k in SPRY stock - Investing.com India
Learn to Evaluate (SPRY) using the Charts - news.stocktradersdaily.com
ARS Pharmaceuticals | 6/18/25 - ktnv.com
FDA Reviewing Oral Epinephrine Film for Possible Approval - Allergic Living
Asthma Market to Expand Significantly by 2034, States - openPR.com
Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier” - Insider Monkey
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ars Pharmaceuticals Inc 주식 (SPRY) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Karas Eric | Chief Commercial Officer |
Jul 01 '25 |
Sale |
16.99 |
15,000 |
254,860 |
10,315 |
Flynn James E | 10% Owner |
Jun 27 '25 |
Sale |
18.46 |
740,149 |
13,663,151 |
4,887,254 |
자본화:
|
볼륨(24시간):